TITLE

MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF ANGINA PECTORIS

AUTHOR(S)
Russek, Henry I.
PUB. DATE
February 1960
SOURCE
Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p76
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Drugs that are effective in the control of anxiety and depression in patients with angina pectoris are important adjuvants in therapy. Tranquilizers and sedatives have been found to reduce nitroglycerin requirements and to increase the capacity for exercise in patients with anxiety symptoms. The low toxicity of the newer hydrazine derivatives has made it possible to utilize these agents for their influence on pain mechanisms and mental depression. No evidence has been found in the present study to suggest that the prevention of myocardial ischemia is an essential component in the observed clinical response. The newer monoamine oxidase inhibitors, although considerably less toxic than iproniazid, are also less effective in the attainment of favorable response. It has been found that the influence on monoamine metabolism, the ability to relieve symptoms, and the frequency of side effects are all inter-related in a quantitative manner. Monoamine oxidase inhibitors are indicated in severe and intractable angina pectoris as well as in milder cases in which disturbing residual symptoms persist despite other forms of therapy. Nitroglycerin and long acting nitrites should always be employed to their full advantage, and it would appear mandatory that they be continued during hydrazine therapy. The risk of exceeding coronary reserve because of a false sense of physical fitness and the absence of the limiting influence of pain although real is not a serious deterrent in therapy when patients are properly selected and supervised, given insight into the method of treatment and guided with respect to necessary restrictions of activity.
ACCESSION #
16365474

 

Related Articles

  • MONOAMINE OXIDASE INHIBITORS AND ANGINA PECTORIS. Winsor, Travis; Zarco, Pedro // Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p67 

    Four monoamine oxidase (MAO) inhibitors, all hydrazine analogs of Marsilid, were studied and it was found that anginal pain was relieved by all of these agents. The most serious side effect was postural hypotension which was most common in patients receiving chlorothiazide and in those with a...

  • INDICATIONS, CONTRAINDICATIONS AND TREATMENT WITH MONOAMINE OXIDASE INHIBITING ANTIDEPRESSANT DRUGS. Sainz, Anthony // Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p94 

    The monoamine oxidase inhibitors, based on modifications of hydrazine, have been defined, and their pharmacologic position, e.g., as antidepressants rather than stimulants, analeptics, etc., has been specifically clarified and documented. An operational classification and definition of the...

  • CORONARY ARTERY DISEASE: THE USE OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF THE ANGINAL SYNDROME. Friedgood, Charles E. // Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p84 

    1. A total of 26 patients with anginal syndrome were treated with Nardil for the relief of pain. 2. Twenty-one patients showed good or excellent response to the daily oral dose of 45 mg. 3. Side effects presented a minor problem in only 1 patient. There appears to be a relation between larger...

  • Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine. Matveychuk, Dmitriy; Nunes, Emerson; Ullah, Nasir; Velázquez-Martinez, Carlos; MacKenzie, Erin; Baker, Glen // Journal of Neural Transmission;Jun2013, Vol. 120 Issue 6, p987 

    Phenelzine is a monoamine oxidase (MAO) inhibitor used in treatment of depression and anxiety disorders. It also elevates brain levels of γ-aminobutyric acid (GABA) and inhibits primary amine oxidase (PrAO), an enzyme whose activity and/or expression has been reported to be increased in...

  • A Compact Clinical Review of Monoamine Oxidase Inhibitors. Fawcett, Jan // Psychiatric Annals;Dec2014, Vol. 44 Issue 12, p548 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the link between monoamine oxidase inhibitors (MAOIs) and atypical depression, various aspects of clinical MAOI use, and a review of the efficacy studies of MAOIs.

  • Severe Serotonin Depletion after Conditional Deletion of the Vesicular Monoamine Transporter 2 Gene in Serotonin Neurons: Neural and Behavioral Consequences. Narboux-Nême, Nicolas; Sagné, Corinne; Doly, Stephane; Diaz, Silvina L; Martin, Cédric B P; Angenard, Gaelle; Martres, Marie-Pascale; Giros, Bruno; Hamon, Michel; Lanfumey, Laurence; Gaspar, Patricia; Mongeau, Raymond // Neuropsychopharmacology;Nov2011, Vol. 36 Issue 12, p2538 

    The vesicular monoamine transporter type 2 gene (VMAT2) has a crucial role in the storage and synaptic release of all monoamines, including serotonin (5-HT). To evaluate the specific role of VMAT2 in 5-HT neurons, we produced a conditional ablation of VMAT2 under control of the serotonin...

  • CYMBALTA.  // AAOS Now;Sep2011, Vol. 5 Issue 9, p1 

    The article offers information on the drug literature of Cymbalta. It notes that Cymbalta is prescribed for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and diabetic peripheral neuropathic pain (DPNP). It notes that Cymbalta is contraindicated for...

  • Dietary inhibitors of monoamine oxidase A. Dixon Clarke, Sarah; Ramsay, Rona // Journal of Neural Transmission;Jul2011, Vol. 118 Issue 7, p1031 

    Inhibition of monoamine oxidase is one way to treat depression and anxiety. The information now available on the pharmacokinetics of flavonoids and of the components of tobacco prompted an exploration of whether a healthy diet (with or without smoking) provides active compounds in amounts...

  • Treating Comorbid Depression and Anxiety. Kuzel, Russel J. // Journal of Family Practice;Dec1996 Supplement, Vol. 43 Issue 6, pS45 

    Depression and anxiety disorders are distinct illnesses that often coexist. Patients suffering from both disorders have more psychological, physical, and social impairment than do patients suffering from either illness alone. Mixed anxiety-depression is gaining recognition as a separate...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics